Drug Trial Radar · NCT05769153
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
139
Actual
Start
Dec 6, 2023
Primary completion
Apr 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Mar 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
Interventions
AR-14034 SR implant lower doseDrug
AR-14034 SR administered as an intravitreal implant
AR-14034 SR implant higher doseDrug
AR-14034 SR administered as an intravitreal implant
AR-14034 SR implantDrug
AR-14034 SR administered as an intravitreal implant
Aflibercept InjectionDrug
Aflibercept administered as a 2 milligram (mg) intravitreal injection
Sham procedureDrug
Needleless syringe used to simulate an intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in ETDRS BCVA at the average across two visits, Weeks 44 and 48 (Stage 2)Time frame: Baseline, Week 44, Week 48
Locations
42 sites in 1 country. Site status is shown where the registry gives one.
Trinity Research Group
Dothan, Alabama
Associated Retina Consultants - Gilbert
Gilbert, Arizona
Associated Retina Consultants - Phoenix
Phoenix, Arizona
Retina Associates of SW PC
Tucson, Arizona
The Retina Partners
Encino, California
Retina Associates of Orange County
Laguna Hills, California
Northern California Retina Vitreous Associates Medical Group
Mountain View, California
Eye Research Foundation
Newport Beach, California
Azul Vision Pasadena
Pasadena, California
Retina Consultants of Southern Colorado
Colorado Springs, Colorado
Retina Group of New England | Waterford
Waterford, Connecticut
Florida Retina Institute
Jacksonville, Florida
Mid Florida Eye Center
Mt. Dora, Florida
Florida Retina Institute
Orlando, Florida
Retina Specialty Institute
Pensacola, Florida
Eye Associates of Pinellas
Pinellas Park, Florida
Center for Retina and Macular Disease
Winter Haven, Florida
Southeast Retina Center
Augusta, Georgia
Thomas Eye Group Main Office
Sandy Springs, Georgia
University Retina and Macula Associates, PC
Oak Forest, Illinois
Twin Cities Eye Consultants
Coon Rapids, Minnesota
Mississippi Retina Associates
Madison, Mississippi
Vision Research Center Eye Associates of New Mexico
Albuquerque, New Mexico
NYC Retina - Queens
Forest Hills, New York
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Verum Research, LLC
Eugene, Oregon
Erie Retina Research
Erie, Pennsylvania
MidAtlantic Retina Research
Philadelphia, Pennsylvania
Retina Consultants of Carolina
Greenville, South Carolina
Carolina Eyecare Physicians LLC
Mt. Pleasant, South Carolina
Retina Research Institute of Texas
Abilene, Texas
Texas Retina Associates - Arlington
Arlington, Texas
Austin Research Center for Retina
Austin, Texas
Austin Retina Associates
Austin, Texas
Austin Clinical Research, LLC
Austin, Texas
Star Vision Research
Burleson, Texas
Texas Retina Associates
Dallas, Texas
Berkeley Eye Center
Houston, Texas
Retina Consultants of Texas - San Antonio
San Antonio, Texas
Austin Retina Associates (San Marcos)
San Marcos, Texas
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.